Skip to main content
Top
Published in: Clinical Rheumatology 8/2018

01-08-2018 | Original Article

Comparative evaluation of therapeutic efficacy of intra-articular oxaceprol with conventional modalities in osteoarthritis animal model

Authors: Harpreet Singh Pawar, Nimmy Kanichai Francis, Tushar Hota, Nabam Peter, Analava Mitra

Published in: Clinical Rheumatology | Issue 8/2018

Login to get access

Abstract

The duration and dose-dependent side effects of conventional intra-articular corticosteroid treatment in osteoarthritis (OA) like cartilage damage and chondrocyte toxicity warrant the search for alternative therapeutics. Oxaceprol, a recognized oral therapeutic agent for osteoarthritis, is yet to be explored for its intra-articular route of administration confirming better safety profile. In this study, a comparative evaluation of intra-articular oxaceprol and corticosteroid is carried out in osteoarthritis rabbit model. Osteoarthritis was induced by monosodium iodoacetate in rabbits. After randomization into three groups of five animals each: OA with intra-articular injection of saline, OA with intra-articular injection of oxaceprol, and OA with intra-articular injection of corticosteroids, treatment efficacy was analyzed by evaluation of inflammation through knee swelling, pain assessment by wire walking, and hot plate method. Further biopsies were collected for histological characterization. Intra-articular oxaceprol and corticosteroids reduced 20.5 and 24.5% knee swelling respectively within 4 weeks compared to those in control osteoarthritic rabbits. Oxaceprol exhibited analgesic action in visual analogue scoring of wire walking method. Hot plate test further confirmed drastic minimization of pain in oxaceprol intervention. Histological investigation suggested that application of oxaceprol has the abilities to protect articular cartilages from degenerative changes that occur in osteoarthritis. Marked improvement both in bone and cellular matrixes was observed in oxaceprol-treated group while gross lesions were visible and consisted of a well-demarcated area of cartilage erosion in control group. Intra-articular injection of oxaceprol showed remarkable improvement of articular cartilage in chemically induced osteoarthritic rabbits.
Literature
1.
go back to reference Plotnikoff R, Karunamuni N, Lytvyak E, Penfold C, Schopflocher D, Imayama I, Johnson ST, Raine K (2015) Osteoarthritis prevalence and modifiable factors: a population study. BMC Public Health 15(1):1195CrossRefPubMedPubMedCentral Plotnikoff R, Karunamuni N, Lytvyak E, Penfold C, Schopflocher D, Imayama I, Johnson ST, Raine K (2015) Osteoarthritis prevalence and modifiable factors: a population study. BMC Public Health 15(1):1195CrossRefPubMedPubMedCentral
2.
go back to reference Jonsson H, Olafsdottir S, Sigurdardottir S, Aspelund T, Eiriksdottir G, Sigurdsson S, Harris TB, Launer L, Gudnason V (2016) Incidence and prevalence of total joint replacements due to osteoarthritis in the elderly: risk factors and factors associated with late life prevalence in the AGES-Reykjavik Study. BMC Musculoskelet Disord 17(1):14CrossRefPubMedPubMedCentral Jonsson H, Olafsdottir S, Sigurdardottir S, Aspelund T, Eiriksdottir G, Sigurdsson S, Harris TB, Launer L, Gudnason V (2016) Incidence and prevalence of total joint replacements due to osteoarthritis in the elderly: risk factors and factors associated with late life prevalence in the AGES-Reykjavik Study. BMC Musculoskelet Disord 17(1):14CrossRefPubMedPubMedCentral
3.
go back to reference Blanco FJ, Guitian R, Vázquez-Martul E, de Toro FJ, Galdo F (1998) Osteoarthritis chondrocytes die by apoptosis: a possible pathway for osteoarthritis pathology. Arthritis Rheumatol 41(2):284–289CrossRef Blanco FJ, Guitian R, Vázquez-Martul E, de Toro FJ, Galdo F (1998) Osteoarthritis chondrocytes die by apoptosis: a possible pathway for osteoarthritis pathology. Arthritis Rheumatol 41(2):284–289CrossRef
4.
go back to reference Henrotin Y, Gharbi M, Dierckxsens Y, Priem F, Marty M, Seidel L, Albert A, Heuse E, Bonnet V, Castermans C (2014) Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complement Altern Med 14(1):159CrossRefPubMedPubMedCentral Henrotin Y, Gharbi M, Dierckxsens Y, Priem F, Marty M, Seidel L, Albert A, Heuse E, Bonnet V, Castermans C (2014) Decrease of a specific biomarker of collagen degradation in osteoarthritis, Coll2-1, by treatment with highly bioavailable curcumin during an exploratory clinical trial. BMC Complement Altern Med 14(1):159CrossRefPubMedPubMedCentral
5.
go back to reference Gelber AC (2015) Conventional medical therapy for osteoarthritis: current state of the evidence. Curr Opin Rheumatol 27(3):312–317CrossRefPubMed Gelber AC (2015) Conventional medical therapy for osteoarthritis: current state of the evidence. Curr Opin Rheumatol 27(3):312–317CrossRefPubMed
6.
go back to reference Herrmann G, Steeger D, Klasser M, Wirbitzky J, Fürst M, Venbrocks R, Rohde H, Jungmichel D, Hildebrandt H, Parnham M (2000) Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac. Clin Rheumatol 19(2):99–104CrossRefPubMed Herrmann G, Steeger D, Klasser M, Wirbitzky J, Fürst M, Venbrocks R, Rohde H, Jungmichel D, Hildebrandt H, Parnham M (2000) Oxaceprol is a well-tolerated therapy for osteoarthritis with efficacy equivalent to diclofenac. Clin Rheumatol 19(2):99–104CrossRefPubMed
7.
go back to reference Chia SL, Sawaji Y, Burleigh A, McLean C, Inglis J, Saklatvala J, Vincent T (2009) Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. Arthritis Rheumatol 60(7):2019–2027CrossRef Chia SL, Sawaji Y, Burleigh A, McLean C, Inglis J, Saklatvala J, Vincent T (2009) Fibroblast growth factor 2 is an intrinsic chondroprotective agent that suppresses ADAMTS-5 and delays cartilage degradation in murine osteoarthritis. Arthritis Rheumatol 60(7):2019–2027CrossRef
8.
go back to reference Shah J, Mirza N, Patel V (2014) A comparative study for safety and efficacy of oxaceprol and diacerein in osteoarthritis of knee joints. PharmaTutor 2(6):108–114 Shah J, Mirza N, Patel V (2014) A comparative study for safety and efficacy of oxaceprol and diacerein in osteoarthritis of knee joints. PharmaTutor 2(6):108–114
9.
go back to reference Kruger K, Klasser M, Mossinger J, Becker U (2007) Oxaceprol—a randomised, placebo-controlled clinical study in osteoarthritis with a non-conventional non-steroidal anti-inflammatory drug. Clin Exp Rheumatol 25(1):29–34PubMed Kruger K, Klasser M, Mossinger J, Becker U (2007) Oxaceprol—a randomised, placebo-controlled clinical study in osteoarthritis with a non-conventional non-steroidal anti-inflammatory drug. Clin Exp Rheumatol 25(1):29–34PubMed
10.
go back to reference Witte S, Lasek R, Victor N (2002) Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis Witte S, Lasek R, Victor N (2002) Meta-analysis of the efficacy of adenosylmethionine and oxaceprol in the treatment of osteoarthritis
11.
go back to reference Gu J, Chen N, Ding G, Zhang Z (2011) Determination of oxaceprol in rat plasma by LC–MS/MS and its application in a pharmacokinetic study. J Pharm Biomed Anal 54(1):173–178CrossRefPubMed Gu J, Chen N, Ding G, Zhang Z (2011) Determination of oxaceprol in rat plasma by LC–MS/MS and its application in a pharmacokinetic study. J Pharm Biomed Anal 54(1):173–178CrossRefPubMed
12.
go back to reference Kim J, Lee EY, Koh E-M, Cha H-S, Yoo B, Lee CK, Lee YJ, Ryu H, Lee KH, Song YW (2009) Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, phase IV study in Korean patients. Clin Ther 31(12):2860–2872CrossRefPubMed Kim J, Lee EY, Koh E-M, Cha H-S, Yoo B, Lee CK, Lee YJ, Ryu H, Lee KH, Song YW (2009) Comparative clinical trial of S-adenosylmethionine versus nabumetone for the treatment of knee osteoarthritis: an 8-week, multicenter, randomized, double-blind, double-dummy, phase IV study in Korean patients. Clin Ther 31(12):2860–2872CrossRefPubMed
13.
go back to reference Riera H, Barbara A, Aprile F, Maheu E, Mitrovic D (1989) Effect of oxaceprol on the synthesis and degradation in vitro of proteoglycans and proteins by calf articular cartilage explants. Revue du rhumatisme et des maladies osteo-articulaires 57(7–8):579–583 Riera H, Barbara A, Aprile F, Maheu E, Mitrovic D (1989) Effect of oxaceprol on the synthesis and degradation in vitro of proteoglycans and proteins by calf articular cartilage explants. Revue du rhumatisme et des maladies osteo-articulaires 57(7–8):579–583
14.
go back to reference Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G (2005) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2 Bellamy N, Campbell J, Robinson V, Gee T, Bourne R, Wells G (2005) Viscosupplementation for the treatment of osteoarthritis of the knee. Cochrane Database Syst Rev 2
15.
go back to reference Kon E, Mandelbaum B, Buda R, Filardo G, Delcogliano M, Timoncini A, Fornasari PM, Giannini S, Marcacci M (2011) Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. Arthroscopy: J Arthrosc Relat Surg 27(11):1490–1501CrossRef Kon E, Mandelbaum B, Buda R, Filardo G, Delcogliano M, Timoncini A, Fornasari PM, Giannini S, Marcacci M (2011) Platelet-rich plasma intra-articular injection versus hyaluronic acid viscosupplementation as treatments for cartilage pathology: from early degeneration to osteoarthritis. Arthroscopy: J Arthrosc Relat Surg 27(11):1490–1501CrossRef
16.
go back to reference Lo GH, LaValley M, McAlindon T, Felson DT (2003) Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 290(23):3115–3121CrossRefPubMed Lo GH, LaValley M, McAlindon T, Felson DT (2003) Intra-articular hyaluronic acid in treatment of knee osteoarthritis: a meta-analysis. JAMA 290(23):3115–3121CrossRefPubMed
17.
go back to reference Sampson S, Gerhardt M, Mandelbaum B (2008) Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Curr Rev Musculoskelet Med 1(3–4):165–174CrossRefPubMedPubMedCentral Sampson S, Gerhardt M, Mandelbaum B (2008) Platelet rich plasma injection grafts for musculoskeletal injuries: a review. Curr Rev Musculoskelet Med 1(3–4):165–174CrossRefPubMedPubMedCentral
18.
go back to reference Spaková T, Rosocha J, Lacko M, Harvanová D, Gharaibeh A (2012) Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil 91(5):411–417CrossRefPubMed Spaková T, Rosocha J, Lacko M, Harvanová D, Gharaibeh A (2012) Treatment of knee joint osteoarthritis with autologous platelet-rich plasma in comparison with hyaluronic acid. Am J Phys Med Rehabil 91(5):411–417CrossRefPubMed
19.
go back to reference Singh H, Francis N, Mitra A (2015) Current trends in osteoarthritis management—a short review. Medicine 3 Singh H, Francis N, Mitra A (2015) Current trends in osteoarthritis management—a short review. Medicine 3
20.
go back to reference Bajpayee AG, Wong CR, Bawendi MG, Frank EH, Grodzinsky AJ (2014) Avidin as a model for charge driven transport into cartilage and drug delivery for treating early stage post-traumatic osteoarthritis. Biomaterials 35(1):538–549CrossRefPubMed Bajpayee AG, Wong CR, Bawendi MG, Frank EH, Grodzinsky AJ (2014) Avidin as a model for charge driven transport into cartilage and drug delivery for treating early stage post-traumatic osteoarthritis. Biomaterials 35(1):538–549CrossRefPubMed
22.
go back to reference Förster K (2000) Drug treatment of osteoarthritis: clinical aspects. Osteoarthritis Berlin Heidelberg New York: Springer-Verlag 66–81 Förster K (2000) Drug treatment of osteoarthritis: clinical aspects. Osteoarthritis Berlin Heidelberg New York: Springer-Verlag 66–81
23.
go back to reference Schuelert N, McDougall JJ (2009) Grading of monosodium iodoacetate-induced osteoarthritis reveals a concentration-dependent sensitization of nociceptors in the knee joint of the rat. Neurosci Lett 465(2):184–188CrossRefPubMed Schuelert N, McDougall JJ (2009) Grading of monosodium iodoacetate-induced osteoarthritis reveals a concentration-dependent sensitization of nociceptors in the knee joint of the rat. Neurosci Lett 465(2):184–188CrossRefPubMed
24.
go back to reference Ionac M, Parnham M, Plauchithiu M, Brune K (1996) Oxaceprol, an atypical inhibitor of inflammation and joint damage. Pharmacol Res 33(6):367–373CrossRefPubMed Ionac M, Parnham M, Plauchithiu M, Brune K (1996) Oxaceprol, an atypical inhibitor of inflammation and joint damage. Pharmacol Res 33(6):367–373CrossRefPubMed
25.
go back to reference Chattopadhyay H, Auddy B, Sur T, Sana S, Datta S (2016) Accentuated transdermal application of glucosamine sulphate attenuates experimental osteoarthritis induced by monosodium iodoacetate. J Mater Chem B 4(25):4470–4481CrossRef Chattopadhyay H, Auddy B, Sur T, Sana S, Datta S (2016) Accentuated transdermal application of glucosamine sulphate attenuates experimental osteoarthritis induced by monosodium iodoacetate. J Mater Chem B 4(25):4470–4481CrossRef
26.
go back to reference Andersen ML, Santos EH, Maria de Lourdes VS, da Silva AA, Tufik S (2004) Evaluation of acute and chronic treatments with Harpagophytum procumbens on Freund’s adjuvant-induced arthritis in rats. J Ethnopharmacol 91(2):325–330CrossRefPubMed Andersen ML, Santos EH, Maria de Lourdes VS, da Silva AA, Tufik S (2004) Evaluation of acute and chronic treatments with Harpagophytum procumbens on Freund’s adjuvant-induced arthritis in rats. J Ethnopharmacol 91(2):325–330CrossRefPubMed
27.
go back to reference Das RK, Anura A, Pal M, Bag S, Majumdar S, Barui A, Chakraborty C, Ray AK, Sengupta S, Paul RR (2013) Epithelio-mesenchymal transitional attributes in oral sub-mucous fibrosis. Exp Mol Pathol 95(3):259–269CrossRefPubMed Das RK, Anura A, Pal M, Bag S, Majumdar S, Barui A, Chakraborty C, Ray AK, Sengupta S, Paul RR (2013) Epithelio-mesenchymal transitional attributes in oral sub-mucous fibrosis. Exp Mol Pathol 95(3):259–269CrossRefPubMed
28.
go back to reference Ostergaard K, Andersen CB, Petersen J, Bendtzen K, Salter DM (1999) Validity of histopathological grading of articular cartilage from osteoarthritic knee joints. Ann Rheum Dis 58(4):208–213CrossRefPubMedPubMedCentral Ostergaard K, Andersen CB, Petersen J, Bendtzen K, Salter DM (1999) Validity of histopathological grading of articular cartilage from osteoarthritic knee joints. Ann Rheum Dis 58(4):208–213CrossRefPubMedPubMedCentral
31.
go back to reference Harris A, Schropp A, Messmer K (1998) Effects of oxaceprol on the microcirculation in ischemia/reperfusion injury. Eur J Med Res 3(4):182–188PubMed Harris A, Schropp A, Messmer K (1998) Effects of oxaceprol on the microcirculation in ischemia/reperfusion injury. Eur J Med Res 3(4):182–188PubMed
32.
go back to reference Lachmann G, Siegemund B, Kusche W (1990) Pharmacokinetics and metabolism of 14C-oxaceprol in beagle dogs after intramuscular and oral administration. Arzneimittelforschung 40(2 Pt 1):200–206PubMed Lachmann G, Siegemund B, Kusche W (1990) Pharmacokinetics and metabolism of 14C-oxaceprol in beagle dogs after intramuscular and oral administration. Arzneimittelforschung 40(2 Pt 1):200–206PubMed
33.
go back to reference Riera H, Aprile F, Mitrovic D (1991) Effet de l’oxacéprol sur la structure des protéoglycannes synthétisés par les chondrocytes articulaires de veau. Revue du rhumatisme et des maladies ostéo-articulaires 58(9):629–634PubMed Riera H, Aprile F, Mitrovic D (1991) Effet de l’oxacéprol sur la structure des protéoglycannes synthétisés par les chondrocytes articulaires de veau. Revue du rhumatisme et des maladies ostéo-articulaires 58(9):629–634PubMed
34.
go back to reference Collins JE, Losina E, Nevitt MC, Roemer FW, Guermazi A, Lynch JA, Katz JN, Kent Kwoh C, Kraus VB, Hunter DJ (2016) Semiquantitative imaging biomarkers of knee osteoarthritis progression: data from the Foundation for the National Institutes of health osteoarthritis biomarkers consortium. Arthritis Rheumatol 68(10):2422–2431CrossRefPubMedPubMedCentral Collins JE, Losina E, Nevitt MC, Roemer FW, Guermazi A, Lynch JA, Katz JN, Kent Kwoh C, Kraus VB, Hunter DJ (2016) Semiquantitative imaging biomarkers of knee osteoarthritis progression: data from the Foundation for the National Institutes of health osteoarthritis biomarkers consortium. Arthritis Rheumatol 68(10):2422–2431CrossRefPubMedPubMedCentral
35.
go back to reference Cone K, Krivitsky R, Warner E, Imbert I, Allen J, Henderson T, Rosen CJ, Bilsky EJ, King T, Stevenson GW (2016) Effects of MIA-induced osteoarthritis on hind limb weight bearing and bone biology endpoints in rats with or without access to running wheels. FASEB J 30(1 Supplement):928.923 Cone K, Krivitsky R, Warner E, Imbert I, Allen J, Henderson T, Rosen CJ, Bilsky EJ, King T, Stevenson GW (2016) Effects of MIA-induced osteoarthritis on hind limb weight bearing and bone biology endpoints in rats with or without access to running wheels. FASEB J 30(1 Supplement):928.923
Metadata
Title
Comparative evaluation of therapeutic efficacy of intra-articular oxaceprol with conventional modalities in osteoarthritis animal model
Authors
Harpreet Singh Pawar
Nimmy Kanichai Francis
Tushar Hota
Nabam Peter
Analava Mitra
Publication date
01-08-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 8/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4087-1

Other articles of this Issue 8/2018

Clinical Rheumatology 8/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.